Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
What's New in Molluscum Contagiosum? Advances in Understanding and Treating Molluscipoxvirus
Description
In this presentation on molluscum contagiosum, Dr. Adelaide Bear discusses recent advancements in understanding and treating this common viral skin infection caused by molluscum contagiosum virus (MCV). Notably, two FDA-approved treatments have emerged: Verdasma gel and Wycamp. Verdasma gel utilizes nitric oxide for its antiviral effects, enhancing immune response, while Wycamp is a cantharidin formulation applied via a user-friendly device. Dr. Bear emphasizes the importance of treating molluscum due to its contagious nature and the psychosocial impact on affected children, particularly those who may miss swimming lessons or social activities. The presentation highlights that while watchful waiting has historically been common, there's increasing consensus for active treatment to alleviate parental concerns as lesions can persist for years. The efficacy of both new treatments has shown significant lesion clearance compared to placebo, thus providing reassurance to parents and healthcare providers. Ultimately, the goal is to help children return to normal activities and mitigate the spread of the infection. Dr. Bear concludes by encouraging attendees to adopt these new strategies in their practices, enhancing care for patients with molluscum contagiosum.
View moreConclusions
- Molluscum contagiosum is an infectious disease caused by a pox virus, predominantly affecting children and showing increasing prevalence among all age groups.
- Close skin-to-skin contact and contaminated objects, including shared towels and toys, are major transmission routes for molluscum contagiosum.
- Patients with atopic dermatitis have a higher propensity for developing molluscum and may experience more severe infections.
- Molluscum lesions can persist for an extended period, sometimes lasting up to five years if untreated, and may lead to significant psychological and social impacts on affected children.
- Two new FDA-approved treatments for molluscum contagiosum — berdazimer gel and VP-102 (cantharidin) — demonstrate efficacy in clearing lesions, with berdazimer gel showing statistically significant improvements over vehicle gel in clinical trials.
- Despite the effectiveness of treatments, a high percentage of cases remain untreated, potentially due to a lack of awareness among pediatricians and caregivers.
- It is critical to treat all affected individuals within a family to prevent the spread of the virus and minimize outbreaks in communal settings, such as schools and swimming pools.
- Badri, T. (2020, April 20). Molluscum Contagiosum. Retrieved July 20, 20, from https://www.ncbi.nlm.nih.gov/books/NBK441898/
- Meza-Romero, R., Navarrete-Dechent, C., & Downey, C. (2019). Molluscum contagiosum: an update and review of new perspectives in etiology, diagnosis, and treatment. Clin Cosmet Investig Dermatol, 12, 373-381. doi:10.2147/CCID.S187224
- Eichenfield, L. F., Hebert, A., Mancini, A., Rosen, T., & Weiss, J. (2021). Therapeutic Approaches and Special Considerations for Treating Molluscum Contagiosum. J Drugs Dermatol, 20(11), 1185-1190. doi:10.36849/jdd.6383
- Silverberg, N. B. (2019). Treatment of molluscum contagiosum in pediatric patients with atopic dermatitis: a review. Cutis, 104(5), 301-305. doi:10.2147/CCID.S187224
- Browning, J. C., Enloe, C., Cartwright, M., et al. (2022). Efficacy and Safety of Topical Nitric Oxide-Releasing Berdazimer Gel in Patients With Molluscum Contagiosum: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. doi:10.1001/jamadermatol.2022.2721